Other Pipeline Programs

We have published complete study results from our Phase I clinical trial with ALN-VSP, an RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. Results from the study – the most comprehensive study of a systemically administered RNAi therapeutic to date – demonstrated proof of RNAi activity in man and evidence of anti-tumor activity, in addition to highlighting the safety and tolerability of multiple doses of ALN-VSP. [spotlight-link icon="release" href="http://cancerdiscovery.aacrjournals.org/content/early/2013/01/26/2159-8290.CD-12-0429"  type=" "] Read the abstract in Cancer Discovery[/spotlight-link][spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=834148"  type=" "] Read our press release[/spotlight-link][spotlight-link icon="presentation" href="https://www.alnylam.com/capella/presentations/aln-vsp-data-presentation-asco-2011/" type="(2.3 MB PDF)"] View our ALN-VSP presentation at ASCO 2011 [/spotlight-link][spotlight-link icon="presentation" href="https://www.alnylam.com/capella/presentations/aln-vsp-asco2012/" type="(2.3 MB PDF)"] View our ALN-VSP presentation at ASCO 2012 [/spotlight-link]

At the annual ASCO meeting in June 2012, we presented data from our ALN-VSP Phase I extension study. Overall, the results demonstrated disease control lasting more than six months in the majority of patients treated on the extension study, including a complete response (CR) in an endometrial cancer patient who had multiple liver metastases. [spotlight-link icon="presentation" href="https://www.alnylam.com/web/assets/ALN-VSP-ExtensionStudyPoster-ASCO-June2012-panel.pdf" type="(3.72 MB PDF)"]View our poster[/spotlight-link] [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734295" type=" "]View our  release[/spotlight-link]


Receive news and updates on the work at Alnylam that affects you most.